Dr. Winnie Yip is a Professor of the Practice of Global Health Policy and Economics at the Harvard T.H. Chan School of Public Health. She serves as Faculty Director of the China Health Partnership and recently concluded her role as Acting Director at Harvard's Fairbank Center for Chinese Studies. Previously, she was a Professor at the University of Oxford and led the Global Health Policy Program. She holds a PhD in Economics from MIT and a BA from UC Berkeley. Her research focuses on systemic healthcare interventions, policy design, and aging populations' impact on health systems. She collaborates closely with governments and international agencies like the World Bank and WHO, advising on reforms in Asia. Her work emphasizes equitable access, health system efficiency, and innovative eldercare solutions. Dr. Yip’s academic leadership includes roles as past President of the International Health Economics Association and editorial positions at journals like Social Science & Medicine . Her grants include funding from NSF, Bill & Melinda Gates Foundation, and EU Commission. Key areas of study include telemedicine, long-term care financing, and healthcare delivery in low-income regions.
Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.
Brooke Hudspeth, PharmD, is an Associate Professor and Chief Practice Officer at the University of Kentucky (UK) College of Pharmacy. She oversees community pharmacy initiatives and serves as acting President of the Kentucky Pharmacists Association (KPhA). Her roles include mentoring pharmacy students and residents as a preceptor, and leading collaborative projects with organizations like the American Pharmacists Association Foundation, Kroger Co., and the CDC. Educationally, she holds a Doctor of Pharmacy from the UK College of Pharmacy, alongside PGY1/PGY2 Community-based Pharmacy Practice Residencies from the same institution. Her research focuses on diabetes prevention, obesity, and pharmacist-driven clinical services, particularly through expanding the National Diabetes Prevention Program (NDPP) to five U.S. states via a $7.5M CDC grant. Research interests emphasize health disparities, vaccine accessibility, and optimizing pharmacist roles in self-care conditions. Notable projects include influenza point-of-care testing and pharmacy partnerships during the pandemic. Her work bridges academic innovation with real-world healthcare challenges, advocating for policy changes to enhance pharmacist payment for clinical services. Despite no explicitly listed awards, her impactful grant-funded projects reflect significant contributions to public health. She advises students and residents while leading residency expansion initiatives. Collaborations with major institutions underscore her role in advancing pharmacy practice and education nationally. Hudspeth’s lab/team is embedded within UK’s College of Pharmacy, focusing on translational research to improve patient care through pharmacist-led interventions. Future work includes expanding telehealth pharmacy services and addressing healthcare workforce shortages.
Ashli Owen-Smith is a behavioral scientist affiliated with the School of Public Health at Georgia State University , where her research focuses on mental health disparities, suicide prevention, and integrative/complementary approaches for complex mental-physical health conditions. She works with underserved populations including refugees/immigrants, incarcerated individuals, and LGBTQ+ communities through community-based participatory research and mixed-methods frameworks. Her current projects are funded by CDC , DBHDD , and DPH . Education: Ph.D. in Behavioral Sciences (Emory, 2009), S.M. in Public Health (Harvard, 2005), B.A. in Psychology (Smith College, 2001) Her research spans mental health , trauma , suicide prevention , and mindfulness-based interventions . Recent work examines telehealth adaptations for chronic pain and mental health, vaccine hesitancy in refugee communities, and social determinants of suicide . She leads studies on gender-affirming care and health disparities in LGBTQ+ populations. Key article trends include epidemiological analysis of suicide risk factors, COVID-19 impacts on mental health, ICD-10 coding for autism, and complementary medicine in trauma recovery. Subfields span telehealth , health equity , mental-physical comorbidity , and community engagement . Students she has mentored include C.A. Scarlett , T. Griner , and M.M. Sesay . Her work integrates public health policy , clinical research , and health systems analysis .
Prof. Dr. Oliver Reiser is a full Professor at the Institute of Organic Chemistry within the Faculty of Chemistry and Pharmacy at the University of Regensburg. His research group focuses on cutting-edge developments in organic synthesis, particularly in the areas of photocatalysis and visible light chemistry. He leads the Collaborative Research Centre CRC 325 on "Assembly Controlled Chemical Photocatalysis," which aims to develop new frontiers in photocatalysis for organic synthesis through designed control of catalyst-substrate interactions. University of Hamburg (PhD, 1989) IBM Research Center (Postdoc) Harvard University (Postdoc) University of Göttingen (Habilitation, 1995) Prof. Reiser's research spans multiple interconnected fields with a strong emphasis on sustainable chemistry. His group extensively utilizes modern techniques for organic synthesis including flow reactors, microwaves, and high-pressure systems. The primary research thrusts include catalysis (both metal and organocatalysts), unnatural amino acids and peptide foldamers, and natural product synthesis. His work on visible light photocatalysis has been particularly influential, with numerous publications in high-impact journals like Angewandte Chemie and Nature Catalysis. The group's research integrates experimental, spectroscopic, and computational techniques to analyze catalyst-substrate interactions for more rational design of photochemical reactions. Analysis of Prof. Reiser's recent publications (2023-2025) reveals a strong focus on copper-based photocatalysis, sustainable chemistry using earth-abundant metals, and innovative approaches to heterocycle synthesis. His work demonstrates a clear trend toward developing more efficient and environmentally friendly catalytic processes, with particular emphasis on visible light activation, catalyst immobilization for recyclability, and applications in medicinal chemistry. The research spans from fundamental mechanistic studies to practical applications in synthesis. German Academic Scholarship Foundation Minerva Foundation NATO Fellowship German Research Foundation Support Karl Winnacker Foundation Prof. Reiser has supervised numerous doctoral students, with recent PhD theses focusing on copper photoredox catalysis, magnetic nanoparticle-supported catalysts, and the synthesis of bioactive compounds. His research is supported by multiple collaborative projects, including the Collaborative Research Centre CRC 325, and involves extensive national and international collaborations with institutions such as the University of Kansas, the National Institute of Chemistry in Pune, the Institut Chimie de Coordination du CNRS in Toulouse, and the University of Zaragoza. The group maintains strong ties with pharmaceutical research through collaborations with Prof. A. Beck-Sickinger in Leipzig on neuropeptide ligands. The research group operates well-equipped laboratories with capabilities for advanced organic synthesis and characterization. They have developed specialized expertise in flow chemistry, high-pressure techniques, and magnetic nanoparticle-based catalyst systems. The CRC 325 initiative has provided significant infrastructure for collaborative research in photocatalysis, bringing together multiple research groups with complementary expertise in organic synthesis, spectroscopy, and computational chemistry.
Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)
Colleen Carey is an Associate Professor at the Jeb E. Brooks School of Public Policy, Cornell University. Her research focuses on the industrial organization of healthcare systems, particularly federal regulation of health insurance markets like Medicare and Medicaid. She examines topics such as reinsurance mechanisms, risk adjustment policies, and the impact of physician-industry financial relationships on prescribing behaviors. Carey is a Faculty Research Fellow at the National Bureau of Economic Research and previously held roles including Robert Wood Johnson Scholar in Health Policy Research and Staff Economist at the Council of Economic Advisers. Education: Bachelor’s Degree: Yale University Ph.D. in Economics: Johns Hopkins University Research Interests: Federal health insurance market design (e.g., ACA marketplaces) Adverse selection mitigation strategies in subsidized insurance Pharmaceutical industry practices and physician prescribing Opioid abuse policy evaluation Social Security Disability Insurance health outcomes Recent Work Trends: Her 2020-2025 publications emphasize healthcare policy evaluation, including analyses of Medicare Advantage enrollment dynamics, racial disparities in disability programs, and the effects of prescription drug marketing on clinical decisions. She consistently bridges economic theory with applied policy analysis. Scientific Awards and Roles: Editorial Board Member, American Journal of Health Economics Robert Wood Johnson Health Policy Research Scholar (2018-2020) NBER Faculty Research Fellow (ongoing) Advising and Grants: Though no formal advisees are listed, her research often involves collaborations with institutions like the Council of Economic Advisers and NBER. She contributes to policy discussions through evidence-based insights. Labs and Teams: Collaborates extensively with NBER’s Health Economics Group and maintains affiliations with Princeton’s Center for Health and Wellbeing.
Arthur Schafer is a Full Professor in the Department of Philosophy at the University of Manitoba's Faculty of Arts and Founding Director of the Centre for Professional and Applied Ethics. He serves as a National Research Associate of the Canadian Centre for Policy Alternatives and previously held roles as ethics consultant for the Winnipeg Regional Health Authority and Head of the Section of Bio-Medical Ethics in the Faculty of Medicine. His academic credentials include a BLitt in Philosophy from the University of Oxford (1967) and a BA Honours from the University of Manitoba. His distinguished career spans over five decades of ethical scholarship and public engagement. Professor Schafer specializes in professional and applied ethics with intensive focus on bioethics , research ethics , and biomedical conflicts of interest . His work critically examines medical assistance in dying , informed consent , clinical trial ethics , and human rights frameworks , establishing him as a leading voice in Canadian ethical discourse. His philosophical approach bridges theoretical rigor with practical policy applications across multiple professional domains. Analysis of his 13 most recent publications reveals enduring engagement with evolving ethical challenges, particularly the tension between institutional interests and professional integrity. His scholarship demonstrates consistent progression from foundational ethical theory toward contemporary policy applications, with recent work heavily concentrated on medical assistance in dying and pharmaceutical industry influence in healthcare systems. His scientific recognition includes: D. R. Campbell Outreach Award (1984) Olive Beatrice Stanton Award for Excellence in Teaching (1976) Canadian Commonwealth Scholarship (1964) Woodrow Wilson Fellowship (1964) Canada Council Fellow As an active supervisor for Master's and PhD students, Schafer extends his mentorship through ethics consulting for professional associations in Medicine, Engineering, Architecture, Nursing, and Pharmacy. His policy impact is evidenced by service on the Provincial-Territorial Expert Panel on Medical Assistance in Dying and two published reports for the Canadian Centre for Policy Alternatives. His extensive media contributions—including hundreds of CBC appearances and newspaper columns—demonstrate exceptional public scholarship. The Centre for Professional and Applied Ethics, which he founded, functions as a vital interdisciplinary hub connecting academic philosophy with real-world ethical challenges across healthcare, law, and public policy sectors, facilitating ongoing dialogue between scholars, practitioners, and community stakeholders.
Liang Zhao, PhD, MAS, MBA, is a Professor in the Department of Bioengineering and Therapeutic Sciences within the Schools of Pharmacy and Medicine at the University of California, San Francisco (UCSF). Prior to joining UCSF, he served as director of the Division of Quantitative Methods and Modeling (DQMM) in the Office of Research and Standards in the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) from 2015 to 2024. His professional career spans over 19 years with experience at Pharsight, Bristol Myers Squibb (BMS), MedImmune, and the FDA. Dr. Zhao's research focuses on pharmacometrics, drug delivery modeling, and artificial intelligence-based tools that impact drug development and regulatory decision-making. His work encompasses mechanistic models for brain drug delivery, regulatory science modeling and simulation, AI-driven drug discovery and development, drug interactions, biological availability, generic drugs, clinical pharmacology, therapeutic equivalency, computer simulation, and FDA regulatory processes. He has pioneered innovative approaches including model master files for model sharing and model-integrated evidence for generic product development and approval. His research integrates machine learning tools into pharmacometrics to advance drug delivery and bioequivalence assessment methodologies. Dr. Zhao has published over 120 articles and book chapters in prestigious journals. His recent publications demonstrate strong focus on applying advanced modeling techniques, machine learning algorithms, and pharmacometric approaches to solve complex problems in drug development and regulatory science. His work shows consistent innovation in developing quantitative methods to enhance bioequivalence assessment, improve drug product characterization, and support regulatory decision-making for generic drugs. FDA Group Recognition Award, FDA, 2024 Gary Neil Prize for Innovation in Drug Development, American Society for Clinical Pharmacology & Therapeutics (ASCPT), 2023 Commissioner's Special Citation, FDA, 2021 Humanitarian Award, Victims' Rights Foundation, 2020 30+ FDA CDER team and Individual Awards, CDER, FDA, 2011 Academic Award for Executive MBA Class 2009, Judge Business School, University of Cambridge, 2011 Dr. Zhao leads the Zhao Lab at UCSF, which advances drug development and regulatory science through cutting-edge research in pharmacometrics, drug delivery modeling, and artificial intelligence. His work bridges academic research with regulatory applications, demonstrating leadership in translating scientific innovations into practical regulatory frameworks. His experience across industry, regulatory agencies, and academia provides a unique perspective on drug development challenges and opportunities.
Professor Hak-Kim Chan of the Sydney Pharmacy School at the University of Sydney is a world-renowned expert in respiratory drug delivery, particularly pulmonary aerosols and inhalation therapies. With over 480 publications and 17,580+ Google Scholar citations, he has pioneered advancements in powder formulation , in silico modeling , and clinical applications of inhalation technologies. His work includes the development of FDA-approved diagnostics like Aridol™ (inhaled mannitol for asthma) and Bronchitol™ (for cystic fibrosis), and groundbreaking research on inhaled bacteriophage therapy to combat antibiotic-resistant respiratory infections. Education: BPharm (University Medal, 1983), PhD (1988), DSc (2009) from University of Sydney Professional Experience: Postdoc at University of Minnesota (1988–89), Scientist at Genentech Inc. (1992–95) Leadership: Executive Editor of Advanced Drug Delivery Reviews , Fellow of AAPS and RACI His research spans in vitro production methods, computational modeling of inhaler design, and in vivo imaging of aerosol deposition. Current projects focus on nanomedicine , phage therapy , and combating superbugs via inhalation routes. He has secured significant recognition for his work, including NHMRC case studies highlighting public health impacts. Professor Chan has supervised numerous researchers, including PhD student Grace YAU studying pulmonary probiotic delivery . His team's 10 patents (7 as first inventor) reflect practical innovations in dry powder inhalers , antimicrobial formulations , and drug stabilization technologies.
Benjamin Andrew Toll is a Professor in the Department of Public Health Sciences and Psychiatry at the Medical University of South Carolina (MUSC) College of Medicine. He serves as Associate Director of Education and Training for the Hollings Cancer Center, Vice Chair of Research in the Department of Public Health Sciences, Co-Director of the Lung Cancer Screening Program, and Director of the Tobacco Treatment Program at MUSC. Dr. Toll received his BA from Cornell University (1996), MS and PhD from Nova Southeastern University (1999, 2002), and completed his Postdoctoral Fellowship and Internship at Yale University. Dr. Toll is a leading researcher in tobacco cessation, with over 20 years of experience conducting clinical trials focused on developing novel therapeutics for tobacco and nicotine use. His work primarily centers on preventing cancer through tobacco treatment interventions, with particular emphasis on lung cancer screening patients and cancer surgery patients. He has expertise in nicotine replacement therapy, contingency management approaches, gain-framed messaging, and digital health interventions for smoking cessation across diverse populations including older adults and young adults. His recent publications demonstrate a strong focus on implementation science for tobacco treatment programs across various healthcare settings including hospitals, oncology clinics, and primary care. His research examines barriers to treatment, optimal delivery methods (including telehealth and EHR-integrated tools), and effectiveness of various pharmacological and behavioral interventions for smoking cessation. National Cancer Institute funding (R01CA235697, R01CA207229, P50CA196530) National Institute on Drug Abuse funding (P50DA036151, K12DA000167) Continuous funding for over 15 years for tobacco cessation research As a mentor and leader, Dr. Toll oversees the Education and Training program at the Hollings Cancer Center, guiding the development of future cancer researchers. His Tobacco Treatment Program serves as a model for integrating tobacco cessation into comprehensive cancer care, and he has successfully implemented 'opt-out' tobacco treatment programs across multiple hospital systems in South Carolina. Dr. Toll leads a multidisciplinary research team focused on tobacco treatment, including psychologists, pharmacists, physicians, and implementation scientists working together to develop and test innovative approaches to smoking cessation for high-risk populations.
Dr. Thomas Chen is an Assistant Professor in the Department of Medicine-Hospital Medicine at the University of Chicago. He serves as Co-Director of the Personalized Therapeutics Clinic, focusing on integrating pharmacogenomics into clinical practice. Dr. Chen's primary research interests include pharmacogenomics, medical education, and hospital medicine. He has particular expertise in the medication reconciliation process, prescribing practices, and quality improvements that decrease healthcare costs while improving patient outcomes. His work bridges the gap between genomic medicine and practical clinical applications in hospital settings. Dr. Chen has made significant contributions to the implementation of pharmacogenomics in inpatient care. His research demonstrates how pharmacogenomic information can be effectively integrated into routine hospital practice to improve patient care, with a focus on care team dynamics, applicability for minority populations, and outcomes of various medication regimens in hospitalized patients. His work shows a clear trend toward practical implementation of pharmacogenomics in real-world clinical settings, with publications spanning from diagnostic methods (2012) to current cutting-edge research on care team attributes predicting successful pharmacogenomic implementation (2025). Dr. Chen holds dual training in pharmacy and medicine, providing him with a unique perspective on medication management and pharmacogenomics. His research has been published in high-impact journals including Clinical and Translational Science, Pharmacogenetics and Genomics, and Journal of Personalized Medicine.
Professor David Alldred is a Professor of Medicines Use and Safety at the University of Leeds' School of Healthcare, within the Faculty of Medicine and Health. His expertise spans medicines optimisation, patient safety, deprescribing, and care home medication management. He leads key research initiatives such as the NIHR Yorkshire and Humber Patient Safety Research Collaboration's 'Decluttering Safely for Safety' theme and co-leads the School of Healthcare's Quality and Safety research theme. Education: PhD (clinical research on care home medication review), MSc in Clinical Pharmacy, PGCert in Learning and Teaching, and BPharm (Hons). Professional memberships include Fellowships of the Royal Pharmaceutical Society and the Higher Education Academy. Research focuses on improving medication use for older adults in care homes and underserved populations, employing systematic reviews, qualitative studies, and RCTs. Notable projects include the CHUMS study (Department of Health-funded medication error analysis in care homes) and leadership roles in NIHR Programme Grants like CHIPPS and CHARMER. He collaborates with NHS England to implement medicines optimisation programs and co-designed multilingual medication review resources to reduce health inequalities. Awards include the Pharmacy Practice UK Research Award (2015) and NIHR Senior Investigator status (2025). His work emphasizes translating evidence into clinical practice, with over 150 publications and supervising NIHR-funded doctoral students in critical care, diabetes, cystic fibrosis, and geriatrics. Led the Care Homes' Use of Medicines Study (CHUMS), contributed to NICE guidelines for care home medicines management, and developed interventions like the Medicines at Transitions Intervention (MaTI) for heart failure patients. His research themes address polypharmacy reduction, medication safety across care transitions, and pharmacist-led deprescribing strategies.
Dr. Kenji Fujita is a Research Fellow at the Kolling Institute, University of Sydney, specializing in ageing, pharmacology, and pharmaceutical care quality. He holds a PhD, MScMed (ClinEpid), and BPharm from the University of Sydney. Previously a pharmacist in Japan, he leads international initiatives in the Pharmaceutical Care Network Europe (PCNE) and the International Pharmaceutical Federation (FIP). His work focuses on deprescribing strategies, polypharmacy, and developing quality indicators for healthcare services. Dr. Fujita’s research integrates big data analysis, statistical modeling, and machine learning to address challenges in geriatric pharmacotherapy. Current projects include validating frailty indices, evaluating deprescribing interventions in older adults, and developing NLP tools for clinical documentation analysis. He has also contributed to assessing organizational readiness for guideline implementation in community pharmacies. Awards include the 2023 Outstanding Poster Presentation Award at the IAGG Asia/Oceania Congress and 2022 Best Poster at the Japanese Society of Social Pharmacy. He has secured grants such as the 2024 electronic frailty index project and the 2021 systems-approach to medication review initiative. Dr. Fujita collaborates with global networks like J-HOP (Japan Home Visiting Pharmacy Association) and leads multidisciplinary teams across Australia and Europe. His lab focuses on translating data-driven insights into actionable clinical practices to improve medication safety and quality in ageing populations.
Nashwa Masnoon is a Postdoctoral Research Fellow in Geriatric Pharmacotherapy at the Kolling Institute, part of the Faculty of Medicine and Health at the University of Sydney. She is also a hospital pharmacist at the Royal North Shore Hospital. Her academic background includes a BPharm(Hons) and a PhD from the University of South Australia, where her doctoral work focused on identifying risks of adverse outcomes from polypharmacy in older adults with multimorbidity. Dr Masnoon’s research interests span geriatric pharmacology, deprescribing practices, pharmacoepidemiology, and quality use of medicines. Her current projects include developing stewardship programs for anticholinergic/sedative deprescribing, optimizing medication use in hospitals for older patients, and educating hospital pharmacists using the Drug Burden Index intervention bundle. She has co-supervised Honours students in 2022 and 2023, focusing on deprescribing in hospital settings and patient-reported experiences post-intervention. Research Themes: Healthy Ageing Key Approaches: Systematic reviews, clinical interventions, pharmacoepidemiological analysis Dr Masnoon has received notable awards including the 2023 FMH Showcase Travel Award, Royal North Shore Hospital Travel Fellowship (2023), and a 2017 People’s Choice Award for her 3 Minute Thesis presentation. Her work emphasizes improving medication outcomes through evidence-based deprescribing and precision medicine approaches. She is affiliated with the Australasian Pharmaceutical Science Association (APSA), International Pharmaceutical Federation (FIP), and Australian Deprescribing Network (ADeN). Her grants include the 2024 electronic frailty index project and a 2022 travel award-funded initiative.
